Protara Therapeutics, Inc. announced on April 15, 2025, the appointment of Leonardo Viana Nicacio, M.D., as its new Chief Medical Officer. Dr. Nicacio brings nearly 20 years of extensive experience in oncology, drug development, regulatory affairs, and commercial strategy from leading biopharmaceutical and health technology companies.
Prior to joining Protara, Dr. Nicacio served as Head of Clinical Development and Global Medical Affairs at Stemline Therapeutics and held increasing responsibilities at Seagen, including Vice President, Clinical Development. His expertise spans various cancer types, including bladder, breast, and gynecologic cancers.
Dr. Nicacio's guidance is expected to be instrumental as Protara advances its therapeutic candidates for underserved cancers and rare diseases. His appointment comes at a time when the company anticipates several important milestones, including the presentation of interim data from the ADVANCED-2 clinical trial of TARA-002 in NMIBC later in April 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.